Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency

AIMS: Early‐onset emphysema attributed to α‐1 antitrypsin deficiency (AATD) is frequently overlooked and undertreated. RAPID‐RCT/RAPID‐OLE, the largest clinical trials of purified human α‐1 proteinase inhibitor (A(1)‐PI; 60 mg kg(–1) week(–1)) therapy completed to date, demonstrated for the first ti...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Clin Pharmacol
Glavni autori: Tortorici, Michael A., Rogers, James A., Vit, Oliver, Bexon, Martin, Sandhaus, Robert A., Burdon, Jonathan, Chorostowska‐Wynimko, Joanna, Thompson, Philip, Stocks, James, McElvaney, Noel G., Chapman, Kenneth R., Edelman, Jonathan M.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Pharmacodynamics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651313/
https://ncbi.nlm.nih.gov/pubmed/28662542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13358
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items